10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
AVROBIO, which is developing stem cell gene therapies to cure rare lysosomal storage diseases, raised $100 million by offering 5.25 million shares at $19, above the proposed range. It had originally planned to raise $75 million by offering 4.4 million...read more
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
AVROBIO, which is developing stem cell gene therapies to cure rare diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. Insiders intend to...read more
US IPO Weekly Recap: Biotechs boom in a 13-deal torrent
10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Gene therapy biotech AVROBIO prices upsized IPO above the range at $19
AVROBIO, which is developing stem cell gene therapies to cure rare lysosomal storage diseases, raised $100 million by offering 5.25 million shares at $19, above the proposed range. It had originally planned to raise $75 million by offering 4.4 million...read more
US IPO Week Ahead: Health care deals lead 11-IPO week
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Gene therapy biotech AVROBIO sets terms for $75 million IPO
AVROBIO, which is developing stem cell gene therapies to cure rare diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. Insiders intend to...read more